|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
1994-8-4
|
|
pubmed:abstractText |
To assess the prognostic significance of serum prostate-specific antigen (PSA) in the monitoring of patients with localized prostate cancer treated with primary radiation therapy, we analyzed the data from 179 patients treated at our institution between 1987 and 1990.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1402-7
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:7517443-Actuarial Analysis,
pubmed-meshheading:7517443-Adenocarcinoma,
pubmed-meshheading:7517443-Aged,
pubmed-meshheading:7517443-Aged, 80 and over,
pubmed-meshheading:7517443-Analysis of Variance,
pubmed-meshheading:7517443-Humans,
pubmed-meshheading:7517443-Male,
pubmed-meshheading:7517443-Middle Aged,
pubmed-meshheading:7517443-Neoplasm Recurrence, Local,
pubmed-meshheading:7517443-Prognosis,
pubmed-meshheading:7517443-Proportional Hazards Models,
pubmed-meshheading:7517443-Prostate-Specific Antigen,
pubmed-meshheading:7517443-Prostatic Neoplasms,
pubmed-meshheading:7517443-Radiotherapy Dosage,
pubmed-meshheading:7517443-Survival Analysis,
pubmed-meshheading:7517443-Treatment Outcome
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
|
|
pubmed:affiliation |
Department of Urological Oncology, Clinique Ste Catherine, Avignon, France.
|
|
pubmed:publicationType |
Journal Article
|
